NASDAQ: $GLMD
Brain metastasis (BM) remains one of the most formidable challenges in modern oncology. Despite the availability of surgical intervention, radiation, and immunotherapy, the prognosis for patients remains grim, with a 2-year survival rate currently standing below 10%. However, a new partnership between Galmed Pharmaceuticals and Tel Aviv University (TAU) aims to change this narrative by focusing on the unique metabolic vulnerabilities of metastatic cancer cells.
The Metabolic Vulnerability: The p53 and SCD1 Connection
At the heart of this research collaboration is the relationship between the p53 gene and the SCD1 enzyme. Often referred to as the ‘guardian of the genome,’ p53 plays a crucial role in maintaining cellular health. When p53 is inactivated, cancer cells undergo significant metabolic shifts, allowing them to thrive in the lipid-rich environment of the brain.
Recent studies from TAU have identified that this p53 inactivation leads to the upregulation of SCD1, an enzyme responsible for converting saturated fatty acids into monounsaturated fatty acids. For proliferating cancer cells, this process is essential for membrane production and survival. By targeting this specific metabolic pathway, researchers believe they can starve brain-metastasizing tumors at their source.
Aramchol: A Potential First-in-Class Therapy
Galmed Pharmaceuticals has successfully repurposed its lead candidate, Aramchol, for this neurological challenge. By converting the compound into a brain-penetrant SCD1 inhibitor, Galmed is positioning it as a potentially transformative treatment. Unlike traditional chemotherapy, which may struggle to cross the blood-brain barrier effectively, this modified version of Aramchol is designed to reach the site of the metastasis directly.
A Powerful Research Collaboration
The collaboration agreement, facilitated by Ramot at Tel Aviv University, bridges the gap between genomic discovery and clinical application. Two of TAU’s world-renowned research teams are spearheading the evaluation:
- The Ben-David Lab: Providing the necessary genomic expertise to understand the p53-driven metabolic adaptations of tumor cells.
- The Satchi-Fainaro Lab: Utilizing advanced 3D in vitro and in vivo modeling to simulate the complexity of brain metastases, ensuring that preclinical findings are as predictive of clinical success as possible.
Prof. Ronit Satchi-Fainaro noted that these sophisticated models are vital for translating mechanistic insights into tangible therapeutic strategies, offering a level of tumor complexity that closely mimics the clinical setting.
Looking Ahead
For Galmed Pharmaceuticals, this collaboration is more than a single research project; it is a strategic expansion of their clinical portfolio. While the company has historically focused on liver disease, the movement into GI oncological therapeutics—specifically with the ongoing work at Virginia Commonwealth University’s Massey Comprehensive Cancer Center—demonstrates a commitment to addressing cancers where p53 mutations are prevalent.
As the partnership progresses, the medical community will be watching closely. If the preclinical validation confirms that Aramchol can effectively inhibit SCD1 within the brain, it could offer a long-awaited lifeline to patients facing some of the most aggressive forms of cancer progression.